Tumor Plasticity Interferes with Anti-Tumor Immunity
Tumor Plasticity Interferes with Anti-Tumor Immunity
复制标题
DOI：
10.1615/critrevimmunol.2014010183
复制
发表时间：
2014-01-01
影响因子：
1.3
通讯作者：
Thiery, Jean Paul
中科院分区：
文献类型：
--
作者：
Chouaib, Salem;Janji, Bassam;Thiery, Jean Paul
由于肿瘤细胞的可塑性首次被证明是至关重要的肿瘤促进和免疫监视逃避，它已成为一个问题，深入研究。有几种机制与肿瘤细胞可塑性的获得和免疫逃避有关，包括通过上皮向间质转化（EMT）而丧失上皮表型。我们讨论了最近的证据表明，肿瘤细胞的可塑性可能会导致免疫耐药变异的出现，以及肿瘤微环境如何演变形成这种可塑性。我们认为，靶向癌细胞可塑性是一种新的策略，可以更好地控制耐药变异的出现，并确保更有效的癌症治疗。在这种情况下，创新的综合免疫治疗方法的设计是必要的。
Since tumor cell plasticity was first shown to be crucial in tumor promotion and immune surveillance evasion, it has become an issue of intense investigation. Several mechanisms are associated with the acquisition of tumor cell plasticity and immune evasion, including loss of epithelial phenotype through epithelial-to-mesenchymal transition (EMT). We discuss recent evidence revealing that tumor cell plasticity may lead to the emergence of immunoresistant variants and how the tumor microenvironment evolves to shape this plasticity We argue that targeting carcinoma cell plasticity represents a novel strategy to better control the emergence of resistant variants and to ensure more effective cancer therapies. In this context, the design of innovative integrative immunotherapy approaches is warranted.